Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 12/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415344 | 1.00 | CD274 (0.33) | CD274PDCD1DDB1CRBNPDCD1LG2 | |
| SCHEMBL2415681 | 1.00 | CD274 (0.33) | CD274PDCD1DDB1CRBNPDCD1LG2 | |
| SCHEMBL2412113 | 1.00 | CD274 (0.33) | CD274PDCD1DDB1CRBNPDCD1LG2 | |
| SCHEMBL2412121 | 1.00 | CD274 (0.33) | CD274PDCD1DDB1CRBNPDCD1LG2 | |
| SCHEMBL12971321 | 1.00 | CD274 (0.33) | CD274PDCD1DDB1CRBNPDCD1LG2 | |
| SCHEMBL12971320 | 1.00 | CD274 (0.33) | CD274PDCD1DDB1CRBNPDCD1LG2 | |
| SCHEMBL2409864 | 0.89 | CD274 (0.33) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL2409862 | 0.89 | CD274 (0.33) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL2416025 | 0.89 | DDB1 (0.32) | DDB1CRBNALDH1A1LMNAMAPT | |
| SCHEMBL2410095 | 0.89 | DDB1 (0.32) | CD274PDCD1DDB1CRBNPDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | CD274 2673/4885PDCD1 1388/4885DDB1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.